RxDoctor Payments Data

Gregory Chapman, MD

Cardiovascular Disease · Alabaster, ALNPI 1588641070

Payments from drug & device makers

$880in general payments, 2019–2025

Across 46 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$407
  • Novo Nordisk$254
  • Johnson & Johnson$91
  • Amgen$42
  • Braemar Manufacturing, LLC$40
  • Inspire Medical Systems, Inc.$28
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis21$407
Novo Nordisk12$254
Johnson & Johnson7$91
Amgen3$42
Braemar Manufacturing, LLC1$40
Inspire Medical Systems, Inc.1$28
Tactile Systems Technology Inc1$18

How this compares

$880 in reported general payments places this provider in the 25th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$216,741
Medicare patients
1,254
Services billed
3,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban428$461,693
XareltoRivaroxaban145$167,438
Repatha SureclickEvolocumab136$101,717
EntrestoSacubitril/Valsartan72$70,260
JardianceEmpagliflozin25$29,315
Praluent PenAlirocumab54$25,018
Rosuvastatin Calcium610$16,471
MultaqDronedarone Hcl11$11,373
Atorvastatin Calcium543$9,867
Metoprolol Succinate423$7,393
Flecainide Acetate67$4,935
Losartan Potassium312$4,923
Ranolazine ErRanolazine44$4,154
Diltiazem 24hr Er (Cd)Diltiazem Hcl101$3,773
Valsartan45$3,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$91$167,438145 claims
NovartisEntresto$407$70,26072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Alabaster

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →